Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Diabetic Peripheral Neuropathy Market Grown from 2024 to 2025?
The market size for diabetic peripheral neuropathy has seen a robust growth in past few years. The projections suggest that it will expand from a size of $3.51 billion in 2024 to touch $3.84 billion in 2025, registering a compound annual growth rate (CAGR) of 9.4%. This positive trend during the historic period can be credited to factors like a growing elderly population, increasing cases of diabetes, a rise in healthcare spending, heightened awareness about complications related to diabetes, and a growth in healthcare infrastructure.
What Growth Rate Is Anticipated for the Diabetic Peripheral Neuropathy Market in the Coming Years?
Anticipations are high for robust expansion of the diabetic peripheral neuropathy market size in the ensuing years. The projection is a growth to $5.43 billion by 2029, increasing at a compound annual growth rate (CAGR) of 9.1%. Factors contributing to the growth in the forecast period range from the rising sedentary lifestyles, escalated government involvement and funding, augmented prevalence of neuropathy risk factors, enhanced diagnostic precision, and intensified support for early diagnosis and prevention. Key trends for the forecast period encompass progress in diagnostic technologies, evolution in treatment methodologies, increased funds for research and development, emergence of minimally invasive procedures, and an increased emphasis on collaborative research and development.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21170&type=smp
Who Are the Leading Companies in the Diabetic Peripheral Neuropathy Market?
Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., Mitsubishi Tanabe Pharma Corporation, NeuroMetrix Inc., Regenacy Pharmaceuticals Inc., Helixmith Co. Ltd., Aptinyx Inc., WinSanTor Inc., Sonnet BioTherapeutics Holdings Inc., OLYS Pharma Inc.
What Are the Key Drivers of the Diabetic Peripheral Neuropathy Market?
The rise in health problems related to obesity is anticipated to drive the expansion of the diabetic peripheral neuropathy market. Obesity, defined as excessive accumulation of body fat that can harm health, raises the risk of multiple chronic diseases. The uptick in obesity-associated health issues stems from heightened awareness, lifestyle modifications, and an escalating need for preventative and curative strategies, leading to a surge in healthcare demand. Diabetic peripheral neuropathy is beneficial for managing obesity. It offers crucial insights into nerve damage resulting from obesity-linked conditions, directing personalized interventions to enhance patient wellness and life quality. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based branch of the United Nations responsible for worldwide public health, reported that in 2022, 43% of adults aged over 18 years were categorised as overweight, and 16% were living with obesity. In addition, 37 million children under five were overweight. Among children and adolescents aged between 5 and 19 years, over 390 million were overweight, including 160 million struggling with obesity. Accordingly, the escalation in obesity-associated health problems is fuelling the growth in the diabetic peripheral neuropathy market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21170&type=smp
What Are the Key Market Segments in the Diabetic Peripheral Neuropathy Industry?
The diabetic peripheral neuropathy market covered in this report is segmented –
1) By Disease: Type 2 Diabetic Peripheral Neuropathy, Type 1 Diabetic Peripheral Neuropathy
2) By Treatment: Pain Management Drugs, Gene Therapies
3) By Therapy: Antidepressants, Anticonvulsants
4) By Patient Population: Adult Patients, Geriatric Patients
Subsegments:
1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy, Motor Neuropathy, Autonomic Neuropathy
2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyradiculopathy
What Are the Latest Trends in the Diabetic Peripheral Neuropathy Market?
Significant players in the diabetic peripheral neuropathy market, like Vertex Pharmaceuticals Incorporated, are concentrating on technological advancement through products like NaV1.8 pain signal inhibitors. These offer a sophisticated, non-opioid alternative enhancing pain regulation and overall wellbeing for patients. A NaV1.8 pain signal inhibitor is a unique drug that interrupts the NaV1.8 sodium channel, crucial for transmitting pain signals in sensory neurons, providing respite from acute and neuropathic pain without use of opioids. In April 2024, Vertex Pharmaceuticals Incorporated, a US biotech firm, declared progress in its suzetrigine pain venture, starting a critical Phase 3 program aimed at mitigating pain linked with diabetic peripheral neuropathy (DPN). Suzetrigine, a targeted NaV1.8 pain signal inhibitor, shown to be hopeful in previous investigations, recently gained the Breakthrough Therapy Designation from the FDA for managing DPN related pain.
Access The Full Report Here:
What Are the Key Regional Markets in the Diabetic Peripheral Neuropathy Industry?
North America was the largest region in the diabetic peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21170
This Report Delivers Insight On:
1. How big is the diabetic peripheral neuropathy market, and how is it changing globally?
2. Who are the major companies in the diabetic peripheral neuropathy market, and how are they performing?
3. What are the key opportunities and risks in the diabetic peripheral neuropathy market right now?
4. Which products or customer segments are growing the most in the diabetic peripheral neuropathy market?
5. What factors are helping or slowing down the growth of the diabetic peripheral neuropathy market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model